iBio, Inc. — Form 8-K
Filed August 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
iBio closed an August 2025 public offering with up to $100M gross proceeds (assuming full warrant exercise) led by Balyasny Asset Management, plus a $26M January 2026 private placement led by Frazier Life Sciences, and entered an ATM agreement for up to $100M in common stock with Jefferies. The company advanced IBIO-600 (myostatin antibody) through single ascending dose Phase 1 dosing 31 of 32 planned participants and advanced IBIO-610 (Activin E antibody) into IND-enabling studies; cash and investments totaled $88.0M as of June 30, 2026 versus $8.6M a year prior. R&D spending more than doubled to $19.6M (from $8.3M), driven by $8.4M in consultant/outsourced services and a $2.5M milestone; net loss was $33.0M versus $18.4M prior year.
Why this rating
Massive capital raises ($126M+ deployed or available) are 5.6× company market cap, extending runway to FY2028 and funding clinical transition. Relative to $22.4M market cap, this is transformational for operations, though stock dilution and clinical-stage risk remain.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.42 ▲ 0.01% | at our read · backfill $1.42 | +10 min · backfill $1.42 ▲ 0.00% | +1 hr · backfill $1.38 ▼ 2.43% | +4 hrs · backfill $1.37 ▼ 3.84% |
The stock had already moved -0.01% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.